Category

Life Sciences

How To Commercialise Life Sciences: Focus On The Basics

By | Biotech, Current Affairs, Guest Posts, Knowledge, Life Sciences

Life sciences research can translate into solutions, products and companies that provide significant benefit to both society and the economy. Today’s dynamic ecosystem presents tremendous opportunities for life sciences innovators given technological advances and rapidly changing market realities. Although the environment for commercialisation has changed dramatically over the last few decades, the basic principles of making it a success remain the same. A commercialisation plan enables innovators to set out and communicate their strategy to others. It should offer a clear and concise overview of the technology’s market potential and the planned route to commercialisation. It should also illustrate how…

Read More

Elasmogen Inks Research Agreement To Develop New Class Of Therapeutics

By | Biotech, Client news, Knowledge, Life Sciences, Startups

Congratulations to our client Elasmogen! Elasmogen, a spin-out from Aberdeen University, alongside Canada based Feldan Therapeutics, have announced a research agreement with Amgen to develop and deliver novel intracellular biologics. The collaboration combines the unique capabilities of Feldan’s Shuttle platform and Elasmogen’s soloMER™ technology to develop the delivery system and binding domains for two undisclosed intracellular targets for Amgen. Elasmogen develops new medicines based on antibody-like molecules isolated from sharks, called VNARs (variable new-antigen receptors). VNARs are found in sharks as part of their immune system and have a similar protective role to antibodies present in the human body. The…

Read More

The Ins and Outs of Clinical Trials – Termination

By | Biotech, Knowledge, Life Sciences

Clinical trials are costly, involve numerous parties and depending on the phase of the trial, are a lengthy process. Although it’s unpleasant to talk about how to end a relationship before it’s even begun, a frank and complete discussion at the outset on how a contract is to be terminated amicably will benefit all parties involved. In this post, we’ll address a termination provision that a sponsor, typically a pharmaceutical company, can exercise and negotiate. Such provision is particular to a clinical trial agreement and which can be challenging to negotiate with other parties to the agreement, i.e. the institution…

Read More

Parkinson’s UK Partners With Sheffield University To Create New Spin Out

By | Biotech, Client news, Life Sciences, Startups

Our client, Parkinson’s UK, has just inked a deal with Sheffield University to create a new £1million virtual biotech company, Keapstone Therapeutics. Even though charities and academia have entered into research partnerships before, the partnership between Parkinson’s UK and Sheffield is the first time a charity has approached researchers to launch a spin-out company with the agenda to advance a particular research programme. The Life Sciences team at JAG Shaw Baker has extensive experience with spin-out companies. The team was instrumental in structuring Keapstone Therapeutics in a way that aligned with Parkinson UK’s over-arching charitable objectives, the academic principles of Sheffield University and the requirements of a high-growth company. The…

Read More

Ins and Outs of Clinical Trials: Publication Rights

By | Biotech, Knowledge, Life Sciences

Looking back to our last post in the Ins and Outs series on Confidentiality, you’ll see there’s an obvious disconnect and therefore potential conflict in relation to publication rights between a sponsor and the principal investigator (PI)/institution. Onerous restrictions on publication rights could be counterproductive and unlikely to be accepted by the institution and PI. For a start, it could potentially sour the goodwill and alliance established between the institution, PI and sponsor prior to commencing the clinical trial. Further, sponsors understand that for many institutions and PIs, in addition to facilitating the development of new medicines, conducting clinical trials has the allure…

Read More

Cross Border M&A Success

By | Biotech, Client news, Knowledge, Life Sciences, M&A

In Life Science news, Akarna Therapeutics Ltd. was acquired by Allergan plc (NYSE: AGN) for an upfront cash payment of $50 million. JAG Shaw Baker acted on behalf of New Science Ventures LLC, a New York venture capital fund that invests in novel scientific approaches. New Science Ventures was one of the selling shareholders alongside Third Point Ventures and Forbion Capital Partners. Akarna Therapeutics is a UK company with offices in Cambridge, UK and San Diego, California. Akarna Therapeutic’s lead product candidate (AKN-083) is considered an effective and novel treatment of non-alcoholic steatohepatitis (NASH) and other liver diseases. An M&A…

Read More

The Top Four Tips You Need to Prep For A Biotech IPO

By | Biotech, Current Affairs, Knowledge, Life Sciences, Partner Insight

Biotech companies have fared well recently in the IPO market in both the US and the UK. New legislation in the US has eased access to public markets and the AIM market in London continues to be attractive for emerging biotech companies. If you’re considering an IPO to raise capital for your biotech company, here are the four top tips you need to prep you on how to prepare for your big launch. 1. Intellectual property is key Wrap up any and all Intellectual Property (IP) issues before kicking off an IPO process. Most advisors and investors are not as…

Read More

A New Blog Series: The Ins And Outs Of Clinical Trials

By | Biotech, Knowledge, Life Sciences

In our new 10 part blog series on clinical trials, Sharmela Thevarajaha, Associate, Intellectual Property and Life Sciences, brings her wealth of private practice and in-house experience with clients such as Sanofi and Takeda, to take a look at some key clauses within a sponsor-initiated clinical trial agreement. In the series she highlights the crucial legal, ethical and business issues to consider when negotiating these key provisions including payments, intellectual property, insurance and publication rights. ______ Clinical research collaboration plays a significant role in developing medicines, advancing medical knowledge and enhancing patient care.   Without clinical trials, pharmaceutical companies (the…

Read More

Elasmogen Spins Out Of The University Of Aberdeen

By | Biotech, Client news, Investor and VC News, investors, Life Sciences

In spin out news, we advised Elasmogen on a variety of corporate and commercial matters in connection with its spin out from the University of Aberdeen. Elasmogen is a biologics drug discovery company that specialises in antibody-like proteins called soloMER. Our legal team advised and negotiated on a variety of corporate, commercial and IP agreements, including, a subscription and shareholders’ agreement, patent licence agreements, material transfer, facilities and management and secondment agreements.

Read More

Crossing The Valley Of Death: Funding, Financing And Strategy At Biotech & Money London

By | Events, Life Sciences

On Tuesday, 2 February, 2016, our co-founder James Shaw spoke at the Biotech & Money conference here in London.  The panel, Crossing the Valley of Death: Funding, Financing and Strategy, addressed investment strategy for life sciences companies and looked at the current state of the market for early stage funding, how to bridge funding gaps and how to position the company to raise capital as well as how to approach vesting criteria.   The panel included Sue Staunton, Partner, James Cowper Kreston; Richard Seabrook, Head of Business Development, Innovations, Wellcome Trust; Francois Martelet, CEO, NetScientific; Ayal Ronen, Vice President, FreeMind; and Goncalo de Vasconcelos, CEO, SyndicateRoom.

Read More

A cookie is a small file of letters and numbers that we store on your browser or computer, phone or tablet hard drive if you agree. more information

INFORMATION ABOUT OUR USE OF COOKIES Our website uses cookies to distinguish you from other users of our website. This helps us to provide you with a good experience and also allows us to improve our website. By continuing to browse the website, you are agreeing to our use of cookies. A cookie is a small file of letters and numbers that we store on your browser or computer, phone or tablet hard drive if you agree. We use the following cookies: • Strictly necessary cookies. These are cookies that are required for the operation of our website. They include, for example, cookies that enable you to return to a previous page. • Analytical/performance cookies. They allow us to recognise and count the number of visitors and to see how visitors move around our website when they are using it. This helps us to improve the way our website works, for example, by ensuring that users are finding what they are looking for easily. The analytical/performance cookies are provided on our behalf by Google Inc. to aid with reporting of user behaviour, market research and improving website functionality. This user behaviour is analysed in order to improve this website. To see how this applies to Google Analytics, visit http://www.google.co.uk/intl/en/analytics/privacyoverview.html. You can stop tracking by Google Analytics by visiting https://tools.google.com/dlpage/gaoptout?hl=en-GB. COOKIE DURATION The strictly necessary session cookies are a temporary cookie which remains in the cookie file of your browser until you close the browser. The other cookies will remain in the cookie file of your browser after the closing of the browser, and will become active again when you reopen this website. The different cookies have different expiration dates. Following expiry of a cookie, a new version of that cookie will be downloaded when you next visit this website, unless you have withdrawn your consent in the meantime. You can block cookies by activating the setting on your browser that allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or parts of our website. Contact If you have any queries regarding this cookie policy please contact us at info@jagshawbaker.com.

Close